Latest News

NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells

NUS study shows Artemisinin-ALA co-treatment could destroy cancer cells

Teva to sell assets in global women’s health business for $1.38bn

Teva Pharmaceutical Industries has entered two agreements to divest the remaining stake in its specialist global women’s health business for...

Teva to sell assets in global women’s health business for $1.38bn

Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases

Immunocore has secured up to $40m in investment from Bill & Melinda Gates Foundation to boost the development of soluble T-cell receptor (TCR)-based therapeutics to treat infectious diseases,...

Gates Foundation supports development of Immunocore’s therapeutics for infectious diseases

Amgen and Allergan’s anti-cancer biosimilar Mvasi receives FDA approval

The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) for the treatment of five types of...

Amgen and Allergan’s anti-cancer biosimilar Mvasi receives FDA approval

Aspen to acquire remaining rights to AstraZeneca’s anaesthetic medicines

Aspen Global Incorporated (AGI) has entered an agreement to acquire all the remaining rights to AstraZeneca’s established anaesthetic treatments for an upfront consideration of...

Aspen to acquire remaining rights to AstraZeneca’s anaesthetic medicines

GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD

GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery...

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

M&As this week: Silver Falcon, Adcock Ingram Holdings, Boya Bio-pharmaceutical Group

Financial services provider Silver Falcon plans to acquire biotechnology company Hemogenyx Pharmaceuticals (Hemogenyx Pharma) for £8m...

M&As this week: Silver Falcon, Adcock Ingram Holdings, Boya Bio-pharmaceutical Group

Evotec and MaRS Innovation launch new drug-discovery partnership

German company Evotec and Canada-based MaRS Innovation (MI) have launched a joint partnership ‘LAB150’ in Toronto, Ontario,...

Evotec and MaRS Innovation launch new drug-discovery partnership

Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs

Bristol-Myers Squibb has entered a global collaboration and licence agreement to use Halozyme Therapeutics’ Enhanze drug-delivery technology for the development of its subcutaneously...

Bristol-Myers and Halozyme to develop subcutaneous immuno-oncology drugs

Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment

Onxeo has granted a global exclusive licence to Monopar Therapeutics for its Validive (clonidine mucoadhesive buccal) tablet used to treat severe oral mucositis induced by radiotherapy...

Monopar receives licence to develop Onxeo’s Validive oral mucositis treatment

US FDA advisory committee votes for GSK’s Shingrix to prevent shingles

US FDA advisory committee votes for GSK’s Shingrix to prevent shingles

Fujifilm opens new cell culture process development laboratories in UK

Fujifilm opens new cell culture process development laboratories in UK

Harbour BioMed to develop and commercialise HanAll’s biologic therapies in Greater China

South Korean pharmaceutical company HanAll Biopharma has entered a strategic collaboration and licence agreement with China-based Harbour BioMed for the development, production...

Harbour BioMed to develop and commercialise HanAll’s biologic therapies in Greater China

Janssen to stop further development of JNJ-4178 hepatitis C treatment

Janssen to stop further development of JNJ-4178 hepatitis C treatment

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment

Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody...

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment

Vanderbilt University and Bayer to evaluate new drug candidates for kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer are set to form a strategic research alliance to evaluate new drug candidates for the treatment of kidney...

Vanderbilt University and Bayer to evaluate new drug candidates for kidney diseases

Summit Therapeutics secures $62m contract to develop ridinilazole for CDI treatment

UK-based drug discovery and development company Summit Therapeutics has secured a contract worth up to $62m to support the clinical and regulatory development of ridinilazole for the treatment...

Summit Therapeutics secures $62m contract to develop ridinilazole for CDI treatment

Integra to sell neurosurgery assets to Natus Medical

Integra LifeSciences has signed an agreement to sell certain neurosurgery assets to Natus Medical in a deal valued at $47.5m....

Integra to sell neurosurgery assets to Natus Medical

Regeneron and Sanofi receive FDA’s breakthrough therapy status for CSCC treatment with cemiplimab

US-based Regeneron Pharmaceuticals and French company Sanofi have received breakthrough therapy designation status for cemiplimab (REGN2810) from the US Food and Drug Administration (FDA) to...

Regeneron and Sanofi receive FDA’s breakthrough therapy status for CSCC treatment with cemiplimab

GSK exercises global licence option for Adaptimmune’s NY-ESO-1 T-cell therapy

GlaxoSmithKline (GSK) has exercised the option to obtain an exclusive global licence from Adaptimmune Therapeutics for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1...

GSK exercises global licence option for Adaptimmune’s NY-ESO-1 T-cell therapy
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_946450448